Linked Life Data

11603093

Source:http://linkedlifedata.com/resource/pubmed/id/11603093

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
26
pubmed:dateCreated
2001-10-17
pubmed:abstractText
Saquinavir is an HIV protease inhibitor (PI) which, formulated as a hard-gel capsule (HCG), was the first drug of its class to become available for the treatment of patients with HIV infection. The limited bioavailability of this drug was responsible for a reduced number of prescriptions when new PI were available. Since 1997, combination therapy with ritonavir has improved the pharmacokinetics parameters resulting in a better clinical benefit. Saquinavir (HGC) monotherapy is not yet recommended. Soft gel capsule (SGC) has improved biodisponibility. Efficacy of SQV has been shown in clinical studies in first and second line of treatment with PI. Resistance profile is favorable considering the low level of cross resistance with other PI. Better knowledge of saquinavir could help giving back a place to this drug in the anti HIV arsenal.
pubmed:language
fre
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0755-4982
pubmed:author
pubmed:issnType
Print
pubmed:day
22
pubmed:volume
30
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1299-303
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2001
pubmed:articleTitle
[Value of saquinavir in antiretroviral treatment of adult HIV-1 infection in 2001].
pubmed:affiliation
Service de Médecine interne B, maladies infectieuses, CHU Hôtel Dieu, F44093 Nantes.
pubmed:publicationType
Journal Article, English Abstract, Review